Graham Capital Management L.P. Has $1.03 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)

Graham Capital Management L.P. boosted its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 467.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,669 shares of the medical research company's stock after acquiring an additional 51,626 shares during the period. Graham Capital Management L.P.'s holdings in NeoGenomics were worth $1,033,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NEO. First Light Asset Management LLC increased its position in shares of NeoGenomics by 3.0% during the fourth quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company's stock worth $52,202,000 after acquiring an additional 91,030 shares in the last quarter. Northern Trust Corp boosted its stake in NeoGenomics by 7.4% in the 4th quarter. Northern Trust Corp now owns 1,621,809 shares of the medical research company's stock worth $26,727,000 after purchasing an additional 111,170 shares during the period. Oberweis Asset Management Inc. increased its holdings in NeoGenomics by 7.0% during the 4th quarter. Oberweis Asset Management Inc. now owns 768,700 shares of the medical research company's stock worth $12,668,000 after purchasing an additional 50,000 shares in the last quarter. Greenhouse Funds LLLP increased its holdings in NeoGenomics by 5.3% during the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after purchasing an additional 237,491 shares in the last quarter. Finally, Mirova acquired a new stake in shares of NeoGenomics in the 4th quarter valued at about $1,070,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at NeoGenomics

In other news, CFO Jeffrey Scott Sherman acquired 20,000 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were purchased at an average cost of $7.51 per share, with a total value of $150,200.00. Following the acquisition, the chief financial officer now directly owns 158,494 shares in the company, valued at $1,190,289.94. This represents a 14.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Anthony P. Zook bought 18,900 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were purchased at an average cost of $7.88 per share, with a total value of $148,932.00. Following the acquisition, the chief executive officer now directly owns 18,900 shares of the company's stock, valued at approximately $148,932. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired 65,600 shares of company stock valued at $512,438 in the last quarter. 2.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

NEO has been the subject of several recent research reports. Needham & Company LLC reduced their price objective on NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Leerink Partnrs cut shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group lowered their price objective on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. StockNews.com upgraded shares of NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Piper Sandler set a $12.00 target price on shares of NeoGenomics and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $13.83.

NeoGenomics Stock Performance

Shares of NeoGenomics stock traded up $0.04 during trading on Monday, hitting $8.15. 92,035 shares of the stock were exchanged, compared to its average volume of 1,123,553. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. The company has a fifty day moving average price of $9.01 and a 200-day moving average price of $12.89. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -13.14 and a beta of 1.60. NeoGenomics, Inc. has a 1-year low of $6.08 and a 1-year high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. During the same period last year, the firm earned ($0.02) EPS. NeoGenomics's quarterly revenue was up 7.6% compared to the same quarter last year. As a group, equities analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.